NEW YORK (GenomeWeb News) – SynapDx today announced a collaboration with the Broad Institute to develop next-generation sequencing analysis methods to improve autism diagnostics.
Specifically, the techniques will be aimed at improving test accuracy and clinical utility, Lexington, Mass.-based SynapDx said. The company is currently conducting large, prospective, multicenter studies to analyze blood from children who are being clinically evaluated for autism spectrum disorder.
"Our partnership with the Broad Institute helps advance our mission by developing powerful tools for the analysis of next-generation sequencing data that will have broad application in the detection of autism and beyond," SynapDx VP of Informatics Mark DePristo said in a statement.